At Johnson & Johnson Innovative Medicine, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Johnson & Johnson. We collaborate with the world for the health of everyone in it. “Gross-to-Net” (GTN) refers to the strategic discounts/rebates J&J Innovative Medicine provides to entities such as: the government, commercial insurance payers/providers, and many others throughout the complex pharmaceutical landscape. In this role, you will gain a deep understanding of the US healthcare system and how the brands that you support, operate within it. GTN is an area of critical importance and will continue to be a dynamic environment for years to come with high visibility. The J&J Innovative Medicine Commercial US Gross-To-Net Senior Financial Analysts provides financial leadership and business partner support for all aspects of Gross-to-Net related to a portion of the Established Products Group (EPG) (Stelara/Ustekinumab, Remicade/Infliximab, Simponi, Simponi Aria), the Patriot portfolio, and total EPG GTN consolidations. This will require responsibility for influencing key strategies and business decisions to ensure patient access to our products across the evolving EPG portfolio. Additionally, the individual has channel responsibility for both actuals and forecast cycles of all of US Innovative Medicine for the AIDS Drug Assistance Program (ADAP) channel, Cash Discounts, and Sales Returns Reserve.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior